Global Bacterial Vaginosis Drugs Market- 2020-2027
Global Bacterial Vaginosis Drugs Market is segmented By Drug (Metronidazole (Flagyl, Metrogel-Vaginal, others), Clindamycin (Cleocin, Clindesse, others), Tinidazole (Tindamax), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2020-2027
The Global Bacterial Vaginosis Drugs Market is expected to grow at a high CAGR during the forecasting period (2020-2027).
Bacterial Vaginosis (BV), also referred to as non-specific vaginitis, is a vaginal disorder that produces vaginal discharge due to an overgrowth of certain kinds of bacteria in the vagina. Previously, the condition was named as Gardnerella vaginitis, after the bacteria that were thought to cause the condition. However, now it is called as bacterial vaginosis, reflects the fact that several species of bacteria naturally live in the vaginal area and may grow to excess, rather than an actual infection with foreign bacteria, such as occurs with many sexually-transmitted diseases (STDs).
Bacterial vaginosis is more commonly associated with vulvovaginal symptoms such as itching, discharge, odour, and discomfort. As per the Centers for Disease Control and Prevention (CDC), more than 84% of women suffering from bacterial vaginosis have no symptoms. It is a common disorder of the genital tract among women of reproductive age and the prevalent cause of vaginal discharge and malodor. Bacterial vaginosis may lead to several gynecologic and obstetric complications such as preterm premature rupture of membranes (preterm PROM), preterm delivery and labor, spontaneous abortion, postpartum endometritis, postsurgical infections, post-caesarean-delivery wound infections, and subclinical pelvic inflammatory disease.
Some of the symptoms of bacterial vaginosis include an abnormal amount of vaginal discharge, thin and greyish white vaginal discharge and vaginal odour. Certain risk factors have also been identified that increase the chances of developing Bacterial Vaginosis. These risk factors for BV include antibiotic use, intrauterine devices for birth control, and cigarette smoking.
Bacterial vaginosis is diagnosed by a vaginal swab test, and the treatment for bacterial vaginosis can be done by the usage of antibiotics, vaginal gels and creams, which can change the acidity of the vagina.
Source: DataM Intelligence Analysis (2019)
The global bacterial vaginosis drugs market growth is driven by factors such as the rising incidence of bacterial vaginosis, growing awareness towards women health, and increasing development of drugs for the treatment.
Increasing incidence of bacterial vaginosis is driving market growth.
As per the American Sexual Health Association 2019, BV is a common gynecologic infection, affecting nearly 29% of women in the US. As per the study conducted by David A. Eschenbach et al. (2007), BV is one of the most common infections among sexually active women that is responsive to antibiotics. BV is present in at least 15% of the sexually active population; this makes BV 3–4 times more common than urinary tract infections.
The United States has the highest percentage of prevalent diagnosed and treated patients of BV among the 7MM.
Hence, increasing incidence of bacterial vaginosis is leading to a rise in research and development for its treatment by private manufacturers and research organizations. Several clinical trials are undergoing to expand the potential future of Bacterial Vaginosis drugs.
United States: Bacterial Vaginosis (BV) occurs in one-third of adult women in the United States, which is around 21 million women. Women make around 10 million office visits for vaginal discharge every year. The rising prevalence is associated with cigarette smoking, obesity, being single/never married, prior to pregnancy, and a history of induced abortion.
Gardnerella vaginalis is observed to occur in up to 100% of women with signs and symptoms of bacterial vaginosis and in up to 70% of women with no signs or symptoms of bacterial vaginosis. G. vaginalis has been isolated in up to 80% of the urethras of male sexual partners of women with bacterial vaginosis.
The incidence of bacterial vaginosis in patients attending obstetric clinics is around 10-25% and as high as 30-65% in patients attending sexually transmitted disease clinics.
Some studies have shown that bacterial vaginosis appears to occur more commonly among African American women than non-Hispanic white women.
G. vaginalis infections commonly occur in women of reproductive age. As per some studies, G. vaginalis colonization in prepubertal and virginal girls and boys and cases of bacterial vaginosis occurring in prepubertal and virginal girls.
COVID-19 Impact Analysis
The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global bacterial vaginosis drugs market has an impact on growth from the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.
By Drugs type, Metronidazole is expected hold signifcant market share
Antibiotics are one of the major treatments for bacterial vaginosis. Some of the medications include metronidazole (Flagyl), clindamycin (Cleocin) oral or vaginal suppositories, metronidazole vaginal gel (MetroGel-Vaginal), among others. Metronidazole and clindamycin are mostly preferred to treat Gardnerella infections.
In September 2017, the FDA approved the first single-dose oral treatment secnidazole (Solosec, Symbiomix Therapeutics) for women with bacterial vaginosis. The approval was based on two randomized, placebo-controlled studies which evaluated the efficacy of secnidazole in treatment of bacterial vaginosis. The efficacy was assessed by clinical outcomes evaluated 21-30 days following a single dose of secnidazole.
Some of the drugs used for the treatment of BV include:
Clindamycin (Cleocin): Bacteriostatic antibiotic is against gram-positive aerobes and gram-positive and gram-negative anaerobes. It inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. It is available as a capsule and 2% vaginal cream formulation.
Metronidazole (Flagyl, MetroGel-Vaginal)): Bactericidal antibiotic enters the bacterial cell and is reduced by electron transport proteins. The free radicals are formed, which react with intracellular components and/or DNA and result in subsequent cell death. The antimicrobial spectrum includes many gram-positive and gram-negative anaerobes and protozoal parasites.
Secnidazole (Solosec): Secnidazole is a nitroimidazole derivative, 5-nitroimidazoles enters the bacterial cell as an inactive prodrug where the nitro group is reduced by bacterial enzymes to radical anions. These radical anions interfere with bacterial DNA synthesis of susceptible isolates.
Source: DataM Intelligence Analysis (2019)
North America is dominating the global Bacterial Vaginosis drugs market
The Asia Pacific BV market is anticipated to grow at the fastest growth rate over the forecast period (2020-2027). A high percentage of people belonging to the sexually active age group in developing countries such as India and China is expected to the growing demand for vaginal drugs in the Asia Pacific in the near future. As per the Index Mundi, a data portal that gathers facts and statistics; over 16 crore women in China belonged to the age group of 15–24 years, while more than ten crore women belonged to the age group of 25–54 years, as of July 2016. The Index Mundi statistics also revealed that more than ten crore women in India come under the age group of 15–25 years while more than eight crore women belonging to the age group of 25–54 years. The large presence base of sexually active women that are susceptible to bacterial vaginosis is expected to grow the market for bacterial vaginosis treatment in Asia-Pacific during the forecast period.
North America accounted for the largest market share in 2019 bacterial vaginosis, owing to high awareness among women towards the bacterial vaginosis and its treatment, growing prevalence of the disorder, and rising disposable income. As per the data by the CDC, the prevalence of bacterial vaginosis in the United States is estimated to be around 21.2 million (29.2%) in women aged 14–49 years.
On the other hand, the Middle East & Africa and South America regions are expected to be prospective markets for bacterial vaginosis treatment over the forecast period, owing to rising prevalence of bacterial vaginosis, growing awareness towards the disease and its treatment among women, increasing disposable income, and highly developing health care industry in these regions.
Some of the major players in bacterial vaginosis treatment market include Bayer, Pfizer, Sanofi, Starpharma Holdings, Allergan, AstraZeneca, Cardinal Health, Mylan, Novartis, Sun Pharmaceutical Industries, Symbiomix Therapeutics, and Teva Pharmaceutical Industries.
These companies offer various products, which are being used for treatment of BV. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the bacterial vaginosis drugs market globally.
In August 20th 2020, Daré Bioscience, Inc., a leader in women’s health innovation, announced the publication of a proof of concept study of DARE-BV1 in Clinical and Experimental Obstetrics & Gynecology, an international journal focused on publication of high quality scientific research related to obstetrics and gynecology and women’s health. DARE-BV1 is a novel thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% that is being evaluated as a one-time vaginally administered treatment for bacterial vaginosis (BV).
Bayer AG is a German multinational pharmaceutical and life sciences company headquartered in Leverkusen. Bayer's areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals, seeds and biotechnology products. The Pharmaceuticals Division focuses on prescription products, especially for women's healthcare and cardiology, and also on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The division also comprises the Radiology Business Unit which markets contrast-enhanced diagnostic imaging equipment together with the necessary contrast agents.
CanesBalance® Bacterial Vaginosis (BV) Vaginal Gel: CanesBalance® BV Gel Triple Benefit Formula is an effective 7-day treatment that relieves the symptoms of BV infection. CanesBalance® works by its effect on the vaginal pH which effectively relieves unpleasant odour and abnormal vaginal discharge.
Why Purchase the Report?
Visualize the composition of the bacterial vaginosis drugs market segmentation, by drug and distribution channel highlighting the key commercial assets and players.
Identify commercial opportunities in bacterial vaginosis drugs market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of bacterial vaginosis drugs market - level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global bacterial vaginosis drugs market report would provide an access to an approx. 69 market data table, 66 figures and 250 pages.
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook